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1. Introduction 
The covalent deployment of agonist molecules on 
the surface of a rigid carrier such as TMV represents 
a new concept for obtaining agonists and antagonists 
with strongly enhanced potency and receptor affinity 
in pharmacological assays and in biochemical binding 
tests (review [ 11). A specific example (among others) 
is provided by TMV-enkephalin conjugates, in which 
the potency and the affinity calculated per single 
enkephalin molecule is multiplied lo-SO-fold by the 
attachment to the virons [2]. 
One of several possible xplanations for the 
observed superpotency and superaffinity is based on 
the assumption of a simultaneous interaction between 
more than one agonist molecule of the TMV conju- 
gate and more than one receptor of the cell or vesicle 
surface (cooperative affinity enhancement) [l]. This 
explanation is not easily proved. It is supported, in 
the case of TMV-adrenocorticotropin conjugates, by 
the observation of drastically reduced issociation 
rates of the conjugate-receptor complexes in com- 
parison to those of the complexes between receptors 
and free adrenocorticotropin [3]. The hypothesis of 
‘cooperative affinity enhancement’ would further- 
more require that no superaffinity effects be observed 
when TMV conjugates interact with single, solubilizec 
receptors. 
To investigate this last point, we chose as models 
for such receptors oluble enzymes that can easily 
Abbreviutions: Amino acids and peptides, according to the 
tentative rules and recommendations of the IUPAC-IUB 
Commission of Biochemical Nomenclature (1972) Eur. J. 
Biochem. 27,201-207; TMV, Tobacco mosaic virus wild 
strain; ala, D&nine; Nip, L-p-nitrophenylalanine; Malex, 
6-maleimidohexanoyl 
hydrolyse free enkephalin peptides. Using reversed- 
phase, high-pressure liquid chromatography (HPLC) 
as the analytical system, we were able to show that 
the covalent attachment to TMV-virions strongly 
inhibited the degradation ofenkephalin peptides. This 
finding supported the ‘cooperative affinity hypothesis 
without, however, proving it. It also suggested that 
reduced rates of proteolysis might account for at least 
a part of the observed superpotency and superaffinity 
effects in pharmacological systems. 
In vivo, however, the degradation of enkephalins 
appears to be caused by membrane-bound enzymes 
[4,5]. In this case, ‘cooperative affinity enhancement’ 
might even increase the degradation rates. Preliminary 
studies on enkephahnase [4] in collaboration with 
Professor Roques in Paris have not yet been conclu- 
sive. In this work, we therefore focus our attention 
on the protection against soluble enzymes provided 
by the TMV virion, which might in itself be of general 
applicability in pharmacological and pharmaceutical 
research. 
2. Materials and methods 
2.1. Enzymes and substrates 
Aminopeptidase M (EC 3.4.11 .l, 50 U/mg) was 
purc&sed from Rijhm and Haas GmbH; thermolysin 
(EC 3.4.24.4, 17 U/mg) from Serva; angiotensin- 
converting enzyme (EC 3.4.15.1, B grade, 1.5 U/mg) 
from Calbiochem; and neutral protease (EC 3.4.24.4) 
from Miles Labs. [Mets]-enkephalin (1) and [Leu’l- 
enkephalin (2) were purchased from Bachem AG, and 
[D-Ala2, Leu’]-enkephalin (3) from Peninsula Labs. 
[D-Ala2, LadamantylalanineS]-enkephalin am de (4) 
was the product described in [6]. NOL-[D-Ala’, Leu’]- 
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enkephalyl-NE-(6-maleimidohexanoyl).lysine amide 
(5) and NOL-[D-Ala’, Nip4, Leu5]-enkephalyl-NE- 
(6-maleimidohexanoyl)lysine amide (6) were syn- 
thesized via a classical approach by reaction in solu- 
tion with purification and analysis of intermediates 
(to be published separately). 
The TMV-enkephalin conjugates were prepared 
by addition of the sulfhydryl group of [ Lys(mercapto- 
succinyl)68]-TMV (TMV - SH) [ 71 to the maleimide 
double bonds of 5 or 6 as in [8]. The resulting 
TMV - S-5 and TMV - S-6 contained -150 enke- 
phalin residues bound covalently to the surface of 
the virions (estimation, see [7,8]). 
2.2. Incubations 
The enzyme solutions contained 0.2 mg enzyme/ 
ml buffer solution (0.01 M Tris-HCl t 0.01 M CaC12, 
(pH 7.8); the Ca2+ stabilizes thermolysine and neutral 
protease against autolysis and assures good activity). 
The enkephalin solutions were obtained by dis- 
solving 0.5 mg (0.5-0.8 pmol) of compounds 2,3 
and S/ml of the buffer used for preparing the enzyme 
solutions. Compounds 1, 4 and 6 (0.5 mg/ml) were 
dissolved in the same buffer containing 20% by volume 
of ethanol. 
The reference TMV suspension contained 35 mg/ml 
(2.00 pmol) TMV protein. The TMV - S-5 and 
TMV - S-6 suspensions contained 30.2 mg/ml (1.73 
lumol) TMV protein and 0.12 pmol/ml covalently 
attached 5 or 6. 
Solutions (50 4) containing 1-6, or 100 ~1 of the 
solutions containing TMV, TMV - S-5 or TMV - S-6, 
were incubated with 20 /.d (40 ~1 for the TMV series) 
of enzyme solution for 16 h at 37’C. 
Samples (4 ~1) of the incubations of l-6 were 
injected into the HPLC column system without 
further treatment. The incubation mixtures con- 
taining TMV, TMV - S-5 or TMV - S-6 were freed of 
protein and nucleoprotein by micropartition ultrafil- 
tration in the Amicon Micropartition System MPS1. 
The ultrafdtrate (20 /.d samples) was then subjected 
to HPLC. 
As a control of the possible adsorption of the 
degradation products to either TMV or filtration 
membranes of the MPS-1 system, incubations were 
also made with 100 ~1 TMV solution, 30 ~1 enkephalin 
solutions (1,3) and 20 $ enzyme solution. 
2.3. High-pressure liquid chromatography 
HPLC was carried out with a gradient system com- 
posed of two Model 1 lo-00 Altex pumps, a Rheodyne 
Model 7 12-20 sample injection valve with a 20 /.d 
loop, a Model 1601 Gradient Master controller (Lab- 
oratory Data Control), and a Uvikon Model LCD 725 
spectrophotometer. 
The column was 25 cm long with an inner diam- 
eter of 3.2 mm. It was filled with LiChrosorb RP-8 
(10 pm particles) by a balance-density packing tech- 
nique .
The mobile phase was composed of 0.025 M phos- 
phate buffer (pH 6.8) and acetonitrile (HPLC grade, 
Fluka). The detection was at 220 nm (O.p2 absorbance 
units = full scale). 
The solutions of the enkephalins l-4, before and 
after incubation with enzymes, were chromatographed 
at room temperature, -20°C with a linear gradient 
from 5-20% acetonitrile in 10 min (gradient I), at a 
flow rate of 2 ml/mm The solutions of the enkephalin 
5 and 6 and the ultrafiltrates from the TMV suspen- 
sions were analysed before and after enzymic degra- 
dation with gradients from 5-30% acetonitrile in 
10 min (gradient II) at the same flow rate. 
The gradient elution program was followed by a 
3 min washing step with 50% acetonitrile and, finally, 
the column was equilibrated with 5% acetonitrile. 
2.4. Degradation products 
The products obtained by enzymic hydrolysis 
were identified by comparison of their chromato- 
graphic retention times (HPLC) with those of analyt- 
ically pure synthetic peptides and amino acids avail- 
able in our laboratory. The reference compounds had 
the following retention times (min): Tyr (0.5) Leu 
(1.0) Met (l.l), Tyr-Gly-Gly (1.1) Phe (1.8), Tyr- 
ala-Gly (1.8) Phe-Met (6.6), Gly-Gly-Phe-Leu 
(8.0),Phe-Leu(8.6), 1 (9.6), 2(11.1), 3(11.7)in 
gradient I, and 4 (17.8) Lys(Malex)-NH, (6.3), Tyr- 
ala-Gly-Phe (6.4), Tyr-ala-Gly-Nip (7.3) Leu- 
Lys(Malex)NH2 (8.3), 5 (12.6), 6 (19.5) in gradient II. 
Possible ambiguities resulting from identical retention 
times, e.g., Met and Tyr-Gly-Gly, Phe and Tyr- 
ala-Gly, were usually easily resolved by taking into 
account the presence or absence of other, comple- 
mentary degradation products. Thus, unambiguous 
assignments could be made for all major peptides and 
amino acids obtained by enzymic hydrolysis of our 
educts. 
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3. Results I 3 A 
The results are summarized in fig.1 and illustrated 
in fig.2. 
Aminopeptidase cleaved the TyrI-Gly2 peptide 
bond of 1 and 2, but not the Tyrl-ala2 bond of 
3-6. Fig.2A shows the release of Tyr and Gly-Gly- 
Phe-Leu as main products from 2. A minor compound 
with a retention time of 1.1 min was tentatively iden- 
tified as Tyr-Gly-Gly, because it arose from both 1 
and 2; compounds with retention times correspond- 
ing to Phe-Met and Phe-Leu (here as a shoulder of 
the Gly-Gly-Phe-L.eu peak) were also discerned. 
With thermolysin, the identified products were 
Tyr-Gly-Gly (from 1 and 2), Tyr-ala-Gly (from 3), 
and Phe-Met or Phe-Leu, depending on the educt. 
Fig.2B shows a typical result obtained with 3 after 
16 h incubation; with shorter incubation times (e.g., 
6 h), substantial amounts of educt still emerged at 
11.7 min and the product peaks were smaller. 
1 a tic,n. t 
1 I 
Tyr-Gly-Gly-Flwbkt 
2 a (a),cn.t 
1 1 
Tyr-Gly-Gly-Phe-Leu 
3 0.c.n.t 
Tyr-ala-Glybd_w 
4 
Tyr-.ala-Gly-Phe-b&NH2 
5 ht) n.t ht) 6 n.t 
Tyr-ala-GlyhehdLys-NH2 
hahlex 
Tyr-ala-Gly-Ni$LeuLyoNH2 
Ibex 
Fig.2. Typical HPLC tiacings obtained from: 2 + aminopep- 
tidase [(A) 1 = Tyr, 2 = Tyr-Gly-Gly, 3 = Gly-Gly-Phe- 
Leu + Phe-Leu]; 3 + thermolysin [(B) 1 = Tyr-ala-Gly; 
2 = Phe-Leu]; 5 + thermolysin [(C) 1 = Tyr-ala-Gly-Ph&, 
2 = Leu-Lys(Malex)-NH,, 3 = Tyr-ala-Gly, 4 = Tyr-ala- 
Gly-Phe-Leu]; 6 + thermolysin [(D) 1 = Tyr-ala-Gly- 
Nip, 2 = Leu-Lys(Malex)-NH,]. 
TMV-S-5 TMV-s-6 
Tyr-alaGly-Re-leuL~N+i~ Tyr-ala-Gly-Nip-LedysNH2 
Malex-S-TMV MakxS-TMV 
0 
&z -Co-CHjCHjCH$t$CH~N 
3 
0 
Malex S-TMV = -CO-CH$H$H$H$H~N 
3 
S-TMV 
Fig.1. Enzymic degradation of enkephalins and their ana- 
logues. The points of hydrolysis are indicated by arrows: a, 
aminopeptidase; t, thermolysin; n, neutral protease; c, angio- 
tensin-converting enzyme. Minor degradation is indicated by 
parentheses, e.g. (a). 
Neutral protease and angiotensin-converting 
enzyme both produced essentially the same pattern 
with l-3 as did thermolysin. Catalysis by angiotensin- 
converting enzyme was much weaker, however, due 
to the low activity of the preparation: after 16 h 
incubation, -3O-50% of 3 remained unchanged, 
whereas with thermolysin and neutral protease, only 
Tyr-ala-Gly and Phe-Leu were identified. 
Adamantylalanine in position 5 completely inhib- 
ited the hydrolysis of 4 by all enzymes tested, as 
already demonstrated with thin-layer chromatography 
[61. 
The hexapeptides S and 6 were both hydrolysed 
by neutral protease and thermolysin (angiotensin- 
converting enzyme was not tested), but in a different 
manner: 6 yielded only Tyr-ala-Gly-Nip and Leu- 
Lys(Malex)-NH? (fig.2D), whereas 5 yielded Tyr- 
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ala-Gly-Phe and ‘Leu-Lys(Malex)-NHs as the major 
and Tyr-ala-Gly and Tyr-ala-Gly-Phe-Leu as, 
minor products (fig.2C; Lys(Malex)NHz was not 
resolved). 
TMV - S-5 and TMV - S-6 were not hydrolysed 
in the presence of the different enzymes: no degrada- 
tion products could be detected with the 2 gradient 
systems even after 24 h. Mixtures of TMV with 1 or: 
3, however, yielded the expected degradation products 
of 1 and 3 with no decrease in peak strength. This 
indicates that the produced peptides are not signifi- 
cantly adsorbed to the virus or to the filtration mem- 
brane of the MPS-I system. 
4. Discussion 
Reversed-phase HPLC was found to be a reliable 
and sensitive method for studying the enzyme-catalysed 
hydrolysis of the synthetic enkephalins (1 and 2) and 
their analogues and derivatives (3-6) on the 2.5 pg 
scale. The incubation mixtures containing 10 pg quan- 
tities of enzyme protein were directly injected into 
the columns. Mixtures containing tobacco mosaic 
virus in mg amounts were applied to the columns 
after removal of highXr compounds by ultrafiltration/ 
micropartition without loss of hydrolysis products. 
The hydrolysis of [Met&enkephalin (1) [ Iad 
enkephalin (2), [ala*, LeuJ-enkephalin (3), and [alas, 
Ada&enkephalin amide (4) as test compounds with 
the exopeptidase, aminopeptidase M, and the endo- 
peptidases, thermolysin, neutral protease, and angio- 
tensin-converting enzyme gave the expected, clear-cut 
results. 
A minor cleavage of 1 and 2 between Glya and 
Phe4 by amino-peptidase to produce products with 
the retention times of Tyr-Gly-Gly and Phe-Met or 
Phe-Leu, respectively, is essentially unexplained. It 
probably reflects the presence of endopeptidase activ- 
ity in the enzyme preparation and a small contamina- 
tion of the commercial educts with [D-Tyri]-enke- 
phalins. D-Tyrosine would inhibit the cleavage by 
amino peptidase, and the D-Tyr-Gly-Gly produced 
by endopeptidase activity would have the same reten- 
tion time as LTyr-Gly-Gly, because of the enanti- 
omeric, not diastereomeric, relationship between the 
two. 
The same Glya-Phe4 bond was the major point of 
hydrolysis of l-3 by thermolysin (Bacillus themo- 
proteolyticus), neutral protease (Bacillus subtilis), 
and angiotensinconverting enzyme. These metallo- 
endopeptidases thus behave like the enkephalinases 
Ar and AZ [4,5] which also appear to be Zn-contain- 
ing enzymes [9]. Our observation supports the hypoth- 
esis of the Paris group that the active sites of the 
enkephalinases and of thermolysin have essential fea- 
tures in common [ lo,1 11. The commonality of the 
active sites of thermolysin and of neutral protease 
has already been demonstrated by structural studies 
[12,13]. 
The reason for the comparatively weak action of 
angiotensin-converting enzyme in our examples was 
not studied in detail: it could be the low specific 
activity of the preparation and the fact that, in order 
to keep the chromatographic conditions constant, the 
pH and chloride concentrations were not optimal for 
this enzyme (pH 8.3 and 300 mM [ 141). Clearly, the 
enzyme cleaved l-3 in the same manner as thermo- 
lysin, neutral protease, and the enkephalinases [l 11. 
We confirmed that the very hydrophobic and 
bulky side chain of adamantylalanine inhibits the 
hydrolysis of the Glys-PheJ peptide bond of 4 [6,16]. 
Having thus proved the usefulness of HPLC for 
our work, we turned to the study of compounds 5 
and 6, and of their TMV conjugates, TMV - S-5 and 
TMV - S-6. 
Introduction of the C-terminal Lys(Malex)-NH* 
group had profound effects on the point of enzymic 
hydrolysis by thermolysin and neutral protease. In 5, 
it moved the specificity of hydrolysis from the Glys- 
Phe4 bond to the Phe4--Leus and, to a minor extent, 
the Leus-Lys6 bonds. The p-nitrophenylalanine4 of 
6 so strongly favored the Nipg-Leus cleavage that 
hydrolysis at other points was not detected. 
The attachment of 5 and 6 to [Lys(mercapto- 
succinyl)es]-TMV virions completely inhibited the 
enzyme-catalysed hydrolysis of the peptides. Control 
experiments with 1 and 3 in the presence of TMV 
showed that neither the catalytic action of the 
enzymes nor the recovery of the products of hydro- 
lysis were impaired by the presence of the virus. 
The observed resistance of TMV-enkephalin con- 
jugates, which might partially explain their enhanced 
affinity and potency, raises new questions. In partic- 
ular, why is the productive recognition of TMV-bound 
hormones by their receptors still possible whereas that 
by proteolytic enzymes is very strongly hindered? 
The study of such questions might provide new 
insights into receptor mechanisms and provide clues 
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for devising and preparing agonists with prolonged 
effects at the target-cell level [ 11. 
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